Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF) will release its first quarter 2023 financial results after the market closes on May 10, 2023. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will review the financial outcomes and discuss recent business developments. Profound is known for its incision-free therapies for the ablation of diseased tissue, notably its TULSA-PRO® technology, which offers customizable, radiation-free treatments for prostate issues. The company has also commercialized Sonalleve®, a platform for treating uterine fibroids and palliative pain in bone metastases, which holds multiple regulatory approvals including FDA clearance.
- Profound is set to announce Q1 2023 financial results, indicating ongoing business activity.
- TULSA-PRO® technology approved by CE, Health Canada, and FDA, demonstrating regulatory confidence.
- Sonalleve® platform has multiple approvals, showing potential for growth in various treatment markets.
- None.
TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2023 financial results after market close on Wednesday, May 10, 2023.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
First Quarter 2023 Results Conference Call Details:
| Date: | Wednesday, May 10, 2023 |
| Time: | 4:30 p.m. ET |
| Live Call Registration: | https://register.vevent.com/register/BI314e0d7f1a8048c1a1f4117231db49be |
The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When will Profound Medical announce its first quarter 2023 financial results?
What time is the conference call for Profound Medical's Q1 2023 results?
What technologies does Profound Medical focus on?
What approvals do TULSA-PRO® and Sonalleve® have?
